Skip to content

Intellicheck, Inc. IDN Sec. 174 capitalized costs

Sec. 174 capitalized costs at other companies

OceanFirst Financial logo
OceanFirst FinancialOCFC
$4.97M-9.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$132.84M+102%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$5.17M-73.7%
Kadant logo
KadantKAI
$3.85M-17.8%
NextNRG, Inc. Common Stock logo
NextNRG, Inc. Common StockNXXT
$367.23K+0.1%
Exagen Inc. logo
Exagen Inc.XGN
$1.89M-35.6%

Other financials

Income statement

See full
Revenue$5.5M+12.9%
Gross profit$5.0M+14.4%
Operating income$542.0K+256%
Net income$636.0K+300%
EPS (diluted)$0.03+250%

Balance sheet

See full
Cash & equivalents$10.1M+95.5%
Total equity$21.5M+22.3%
Total assets$27.1M+10.4%

Cash flow

See full
Operating cash flow$445.0K-40.7%
CapEx$33.0K+267%
Free cash flow$412.0K-44.4%

Valuation

See full
Market cap$83.03M-22.3%
P/E37.3×
P/S3.6×-1.6×

Profitability

See full
Gross margin90.7%+0.1pp
Operating margin8.5%
Net margin9.6%
FCF margin7%

Returns & leverage

See full
Return on equity11.4%
Debt / equity
Current ratio+1.0×

Where this comes from

Reported directly by Intellicheck, Inc. in its filing.

Tagged under the XBRL concept idn:DeferredTaxAssetsResearchAndExperimentalExpenseCapitalization.

The official record: Intellicheck, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellicheck, Inc.'s sec. 174 capitalized costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellicheck, Inc.'s sec. 174 capitalized costs?
Intellicheck, Inc. (IDN) reported sec. 174 capitalized costs of $0 in Q4 2025.
How has Intellicheck, Inc.'s sec. 174 capitalized costs changed year-over-year?
Intellicheck, Inc.'s sec. 174 capitalized costs decreased by 100.0% year-over-year, from $365K to $0.
What does sec. 174 capitalized costs mean?
This represents the capitalized costs associated with research and experimental activities that are recognized as deferred tax assets for future recovery. It reflects the tax benefit derived from long-term investment in innovation and product development. Tracking this helps investors understand the potential future tax savings generated by the company's R&D initiatives.